AU2013221585B2 - Antibodies to integrin alphavbeta6 and use of same to treat cancer - Google Patents

Antibodies to integrin alphavbeta6 and use of same to treat cancer Download PDF

Info

Publication number
AU2013221585B2
AU2013221585B2 AU2013221585A AU2013221585A AU2013221585B2 AU 2013221585 B2 AU2013221585 B2 AU 2013221585B2 AU 2013221585 A AU2013221585 A AU 2013221585A AU 2013221585 A AU2013221585 A AU 2013221585A AU 2013221585 B2 AU2013221585 B2 AU 2013221585B2
Authority
AU
Australia
Prior art keywords
seq
antibody
chain variable
variable region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013221585A
Other languages
English (en)
Other versions
AU2013221585A1 (en
Inventor
Maureen Ryan
Django Sussman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of AU2013221585A1 publication Critical patent/AU2013221585A1/en
Application granted granted Critical
Publication of AU2013221585B2 publication Critical patent/AU2013221585B2/en
Assigned to SEAGEN INC. reassignment SEAGEN INC. Request to Amend Deed and Register Assignors: SEATTLE GENETICS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2013221585A 2012-02-17 2013-02-14 Antibodies to integrin alphavbeta6 and use of same to treat cancer Ceased AU2013221585B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261600499P 2012-02-17 2012-02-17
US61/600,499 2012-02-17
US201261602511P 2012-02-23 2012-02-23
US61/602,511 2012-02-23
PCT/US2013/026087 WO2013123152A2 (en) 2012-02-17 2013-02-14 ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER

Publications (2)

Publication Number Publication Date
AU2013221585A1 AU2013221585A1 (en) 2014-08-14
AU2013221585B2 true AU2013221585B2 (en) 2017-03-30

Family

ID=48984888

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013221585A Ceased AU2013221585B2 (en) 2012-02-17 2013-02-14 Antibodies to integrin alphavbeta6 and use of same to treat cancer

Country Status (13)

Country Link
US (5) US9493566B2 (cg-RX-API-DMAC7.html)
EP (1) EP2814509B1 (cg-RX-API-DMAC7.html)
JP (1) JP6273214B2 (cg-RX-API-DMAC7.html)
KR (1) KR102084806B1 (cg-RX-API-DMAC7.html)
CN (2) CN104220094A (cg-RX-API-DMAC7.html)
AU (1) AU2013221585B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014019861A2 (cg-RX-API-DMAC7.html)
CA (1) CA2862319C (cg-RX-API-DMAC7.html)
EA (1) EA031069B1 (cg-RX-API-DMAC7.html)
IL (1) IL233742B (cg-RX-API-DMAC7.html)
MX (1) MX360141B (cg-RX-API-DMAC7.html)
SG (1) SG11201404354UA (cg-RX-API-DMAC7.html)
WO (1) WO2013123152A2 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2789684T3 (en) 2008-05-23 2017-02-20 Siwa Corp Methods and compositions for facilitating regeneration
CN106232625B (zh) * 2013-10-01 2020-04-24 免疫医疗有限公司 治疗和诊断过表达α-V-β-6的癌症的方法
CA3187392A1 (en) 2013-10-15 2015-04-23 Seagen Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
KR20160120777A (ko) 2014-02-17 2016-10-18 시애틀 지네틱스, 인크. 친수성 항체-약물 컨쥬게이트
WO2015164627A1 (en) * 2014-04-23 2015-10-29 Discovery Genomics, Inc. Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer
EP3194439B1 (en) 2014-09-19 2022-01-19 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
CA3006000A1 (en) 2015-12-04 2017-06-08 Seattle Genetics, Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
JP6722293B2 (ja) 2016-02-19 2020-07-15 シワ コーポレーション 終末糖化産物（ａｇｅ）に対する抗体を使用して、がんを治療、転移性がん細胞を殺傷、及びがん転移を予防するための方法及び組成物
JP7073266B2 (ja) 2016-03-25 2022-05-23 シージェン インコーポレイテッド Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2018031690A1 (en) 2016-08-09 2018-02-15 Seattle Genetics, Inc. Drug conjugates with self-stabilizing linkers having improved physiochemical properties
EA201990890A1 (ru) 2016-10-18 2019-10-31 Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида
JP7291624B2 (ja) 2016-11-01 2023-06-15 アローヘッド ファーマシューティカルズ インコーポレイテッド アルファ－ｖベータ－６インテグリンリガンド及びその使用
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
US11730822B2 (en) 2017-03-24 2023-08-22 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
EP3609923A1 (en) 2017-04-13 2020-02-19 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
WO2018201087A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
EP3703700A4 (en) 2017-11-01 2021-08-04 Arrowhead Pharmaceuticals, Inc. INTEGRIN LIGANDS AND USES OF THESE LATEST
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CN111989339A (zh) 2018-02-20 2020-11-24 西雅图基因公司 疏水性奥瑞他汀f化合物及其缀合物
US20240199735A1 (en) * 2019-07-22 2024-06-20 The Methodist Hospital Microfibrillar-Associated Protein 5 (MFAP5)-Targeting Monoclonal Antibodies and Methods for Use in Treating Cancer
TWI884192B (zh) 2019-12-05 2025-05-21 美商西健公司 抗αＶβ６抗體及抗體-藥物結合物
CN115052663A (zh) 2020-01-08 2022-09-13 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
JP2023520930A (ja) 2020-04-10 2023-05-22 シージェン インコーポレイテッド 電荷多様性リンカー
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
IL307421A (en) 2021-04-08 2023-12-01 Arrowhead Pharmaceuticals Inc Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
KR20230171980A (ko) 2021-04-20 2023-12-21 씨젠 인크. 항체 의존성 세포 독성의 조절
CA3221398A1 (en) 2021-05-28 2022-12-01 Seagen Inc. Anthracycline antibody conjugates
PE20242179A1 (es) 2022-03-17 2024-11-07 Seagen Inc Conjugados de camptotecina
EP4634227A1 (en) 2022-12-13 2025-10-22 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024137442A1 (en) 2022-12-21 2024-06-27 Gilead Sciences, Inc. Combination therapy for treating cancer
WO2024263932A2 (en) 2023-06-23 2024-12-26 Mythic Therapeutics, Inc. Itgb6-binding proteins and uses thereof
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006041934A2 (en) * 2004-10-05 2006-04-20 Neuralab Limited Methods and compositions for improving recombinant protein production
US7465449B2 (en) * 2002-03-13 2008-12-16 Biogen Idec Ma Inc. Anti-αvβ6 antibodies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
NZ515955A (en) 1997-08-08 2003-04-29 Univ California Hybridoma producing a monoclonal antibody against beta-6 integrin
ES2437875T3 (es) * 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
CN100509851C (zh) * 2002-03-13 2009-07-08 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
AU2003230929A1 (en) 2002-04-12 2003-10-27 Raven Biotechnologies, Inc. Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
US7241598B2 (en) 2004-06-29 2007-07-10 The Chinese University Of Hong Kong Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
ES2539126T3 (es) * 2004-12-09 2015-06-26 Janssen Biotech, Inc. Inmunoconjugados anti integrina, métodos para su producción y su uso
JP4949373B2 (ja) * 2005-03-10 2012-06-06 モルフォテック、インク． 抗メソテリン抗体
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
AU2006286498A1 (en) 2005-08-31 2007-03-08 Novo Nordisk Health Care Ag Human FVII monoclonal antibodies binding the GLA domain and use thereof
TW200815474A (en) 2006-08-03 2008-04-01 Astrazeneca Ab Antibodies alphaVbeta6 and uses thereof
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
CA2665885A1 (en) 2006-10-19 2008-12-04 The Regents Of The University Of California Treatment and prevention of chronic asthma using antagonists of integrin .alpha.nu.beta.6
EP3064512B1 (en) * 2008-01-11 2023-08-30 The University of Tokyo Anti-cldn6 antibody
CN101977937A (zh) * 2008-01-22 2011-02-16 拜奥根Idec马萨诸塞公司 Ron抗体及其用途
CN101959929B (zh) 2008-03-27 2013-05-01 泰尔茂株式会社 生物体吸收性材料及使用其的生物体内留置物
EP2279209A2 (en) 2008-05-09 2011-02-02 Ablynx NV Amino acid sequences directed against integrins and uses thereof
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
WO2011046309A2 (en) * 2009-10-12 2011-04-21 Korea Research Institute Of Bioscience And Biotechnology A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof
KR101138460B1 (ko) * 2009-10-12 2012-04-26 한국생명공학연구원 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
CN103874707B (zh) 2010-11-19 2017-04-19 卫材R&D管理有限公司 中和抗‑ccl20抗体
WO2013148316A1 (en) 2012-03-29 2013-10-03 Biogen Idec Ma Inc. Biomarkers for use in integrin therapy applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465449B2 (en) * 2002-03-13 2008-12-16 Biogen Idec Ma Inc. Anti-αvβ6 antibodies
WO2006041934A2 (en) * 2004-10-05 2006-04-20 Neuralab Limited Methods and compositions for improving recombinant protein production

Also Published As

Publication number Publication date
CN104220094A (zh) 2014-12-17
US20160376368A1 (en) 2016-12-29
US20210340260A1 (en) 2021-11-04
US20160009806A1 (en) 2016-01-14
IL233742B (en) 2019-08-29
EP2814509A2 (en) 2014-12-24
JP6273214B2 (ja) 2018-01-31
CA2862319C (en) 2021-11-30
US9493566B2 (en) 2016-11-15
CA2862319A1 (en) 2013-08-22
KR102084806B1 (ko) 2020-03-04
EA031069B1 (ru) 2018-11-30
KR20140127875A (ko) 2014-11-04
MX360141B (es) 2018-10-24
CN105017420B (zh) 2019-05-28
EA201491541A1 (ru) 2016-05-31
IL233742A0 (en) 2014-09-30
HK1211035A1 (en) 2016-05-13
AU2013221585A1 (en) 2014-08-14
EP2814509B1 (en) 2018-05-16
US20230242648A1 (en) 2023-08-03
JP2015509938A (ja) 2015-04-02
US20200031938A1 (en) 2020-01-30
EP2814509A4 (en) 2015-12-09
CN105017420A (zh) 2015-11-04
MX2014009751A (es) 2015-02-24
BR112014019861A2 (pt) 2017-07-04
SG11201404354UA (en) 2014-10-30
WO2013123152A2 (en) 2013-08-22
WO2013123152A3 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
US20230242648A1 (en) Antibodies to integrin avb6 and use of same to treat cancer
US20230105802A1 (en) Anti-ntb-a antibodies and related compositions and methods
US20210047404A1 (en) Cd33 antibodies and use of same to treat cancer
US12268751B2 (en) Anti-αVβ6 antibodies and antibody-drug conjugates
EA046934B1 (ru) АНТИТЕЛА ПРОТИВ αvβ6 И КОНЪЮГАТЫ АНТИТЕЛО-ЛЕКАРСТВЕННОЕ СРЕДСТВО
HK1211035B (zh) 針對整聯蛋白αvβ6的抗體和使用該抗體治療癌症

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: SEAGEN INC.

Free format text: FORMER NAME(S): SEATTLE GENETICS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired